Clinical Advances in Hematology and Oncology

0.3(top 100%)

impact factor

2.0K(top 10%)

papers

11.1K(top 20%)

citations

38(top 20%)

h-index

0.4(top 50%)

impact factor

2.5K

all documents

11.3K

doc citations

60(top 20%)

g-index

Top Articles

#	Title	Journal	Year	Citations
1	Osteosarcoma: a review of diagnosis, management, and treatment strategies	Clinical Advances in Hematology and Oncology	2010	320
2	ALK inhibitors in non-small cell lung cancer: crizotinib and beyond	Clinical Advances in Hematology and Oncology	2014	179
3	The BioBank Japan Project	Clinical Advances in Hematology and Oncology	2007	125
4	NSABP B-39, RTOG 0413: A Randomized Phase III Study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer	Clinical Advances in Hematology and Oncology	2006	120
5	Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions	Clinical Advances in Hematology and Oncology	2013	119
6	Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy	Clinical Advances in Hematology and Oncology	2010	112
7	ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy	Clinical Advances in Hematology and Oncology	2003	108
8	Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management	Clinical Advances in Hematology and Oncology	2008	94
9	A review of depression in the head and neck cancer patient	Clinical Advances in Hematology and Oncology	2009	89
10	The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer	Clinical Advances in Hematology and Oncology	2011	82
11	The role of the fallopian tube in ovarian cancer	Clinical Advances in Hematology and Oncology	2012	77
12	Clotting mechanisms and cancer: implications in thrombus formation and tumor progression	Clinical Advances in Hematology and Oncology	2003	75
13	Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins	Clinical Advances in Hematology and Oncology	2009	73
14	CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia	Clinical Advances in Hematology and Oncology	2016	71
15	Angiogenesis inhibition in the treatment of lung cancer	Clinical Advances in Hematology and Oncology	2006	69
16	Role of the androgen receptor in triple-negative breast cancer	Clinical Advances in Hematology and Oncology	2016	68
17	Radon and lung cancer	Clinical Advances in Hematology and Oncology	2012	66
18	Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia	Clinical Advances in Hematology and Oncology	2012	66
19	Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma	Clinical Advances in Hematology and Oncology	2012	62
20	Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives	Clinical Advances in Hematology and Oncology	2018	59
21	Recurrent ovarian cancer	Clinical Advances in Hematology and Oncology	2005	59
22	The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck	Clinical Advances in Hematology and Oncology	2008	58
23	Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme	Clinical Advances in Hematology and Oncology	2007	58
24	Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy	Clinical Advances in Hematology and Oncology	2012	58
25	Chemotherapy in endometrial cancer	Clinical Advances in Hematology and Oncology	2006	51
26	Current controversies in the management of biochemical failure in prostate cancer	Clinical Advances in Hematology and Oncology	2012	50
27	Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses	Clinical Advances in Hematology and Oncology	2014	50
28	Bortezomib: a novel therapy approved for multiple myeloma	Clinical Advances in Hematology and Oncology	2003	49
29	HSP90 inhibitors in lung cancer: promise still unfulfilled	Clinical Advances in Hematology and Oncology	2016	48
30	A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer	Clinical Advances in Hematology and Oncology	2012	46
31	Management of neutropenia in cancer patients	Clinical Advances in Hematology and Oncology	2012	43
32	Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series	Clinical Advances in Hematology and Oncology	2008	43
33	Symptom control issues and supportive care of patients with head and neck cancers	Clinical Advances in Hematology and Oncology	2007	42
34	Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia	Clinical Advances in Hematology and Oncology	2009	42
35	Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy	Clinical Advances in Hematology and Oncology	2004	41
36	Therapeutic advances in the treatment of brain metastases	Clinical Advances in Hematology and Oncology	2007	41
37	Translating Research into Practice: the Prosigna® (PAM50) Gene Signature Assay	Clinical Advances in Hematology and Oncology	2015	40
38	Anemia in multiple myeloma	Clinical Advances in Hematology and Oncology	2004	39
39	Endocrine complications of androgen-deprivation therapy in men with prostate cancer	Clinical Advances in Hematology and Oncology	2006	38
40	Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments	Clinical Advances in Hematology and Oncology	2014	37
41	Acute graft versus host disease: pathophysiology, risk factors, and prevention strategies	Clinical Advances in Hematology and Oncology	2005	36
42	FLT3 inhibitors for the treatment of acute myeloid leukemia	Clinical Advances in Hematology and Oncology	2010	36
43	Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies	Clinical Advances in Hematology and Oncology	2015	36
44	Potential role of recombinant factor VIIa as a hemostatic agent	Clinical Advances in Hematology and Oncology	2003	35
45	PD-1-targeted immunotherapy: recent clinical findings	Clinical Advances in Hematology and Oncology	2012	35
46	Regulation of NF-kB in multiple myeloma: therapeutic implications	Clinical Advances in Hematology and Oncology	2004	34
47	The effect of cancer treatment on cognitive function	Clinical Advances in Hematology and Oncology	2015	34
48	Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia	Clinical Advances in Hematology and Oncology	2013	33
49	Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches	Clinical Advances in Hematology and Oncology	2005	33
50	Risks of blood transfusion and their prevention	Clinical Advances in Hematology and Oncology	2003	33

Scientometrics

Overviews

Citing Bodies

Clinical Advances in Hematology and Oncology

Top Articles